Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is committed to continuous innovation and leveraging advanced robotics and AI technologies [10] Other Important Information - The company plans to increase investment in R&D to advance new products to market, including a recently acquired powered upper body exoskeleton [21] - The company will not provide guidance at this time due to significant transformations and pending agreements [14] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][31] Question: What is the timeline for the upper extremity robotic assistance product? - Management expects the product to take 18-24 months to complete, with a low barrier to entry for regulatory approval [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing resilience and multiple opportunities for product commercialization [42][43] Question: What drove the additional execution in revenue? - Management attributed the revenue performance to improved understanding of reimbursement pathways and better payer coverage, with expectations for continued growth [49][50]

Group 1: Healthcare Stocks Overview - Many healthcare stocks, including small-cap biotech companies, are trading below $50 per share, but many are high-risk investments that may not yield long-term wealth for investors [1] - There are high-quality healthcare corporations available for investment at this price point, excluding fractional shares [1] Group 2: Pfizer and Novo Nordisk - Pfizer's shares are currently priced just under $27, trading at 9x forward earnings, significantly lower than the healthcare industry's average forward price-to-earnings of 17.8 [2] - Pfizer has faced inconsistent financial results, primarily due to lower sales from its coronavirus franchise, but is expected to improve as dependence on these products declines [3] - Novo Nordisk's stock price is around $39 with a forward price-to-earnings ratio of 10.4, and it is well-positioned to benefit from the expanding weight-loss market [3] - Novo Nordisk's weight-loss medicines, such as Wegovy, are leaders in their niches, and the company has several pipeline candidates that could receive approval in the coming years [4] Group 3: Exelixis - Exelixis, while not a major name in biotech, has established a niche in oncology with its therapy Cabometyx, which treats certain forms of liver and kidney cancer [5] - The company has been reporting growing revenue and earnings, and it may achieve further label expansions for Cabometyx before facing generic competition in early 2030 [5]

Core Viewpoint - Equillium, Inc. is actively engaging with investors at the upcoming 38th Annual Roth Conference for Growth Companies, highlighting its commitment to transparency and investor relations [1]. Company Overview - Equillium is a biotechnology innovator focused on developing novel therapies for severe autoimmune and inflammatory disorders [2]. - The company's lead therapeutic candidate, EQ504, is designed as a potent and selective aryl hydrocarbon receptor modulator with a non-immunosuppressive mechanism of action [2]. - EQ504 has potential applications for targeted local delivery in treating ulcerative colitis and other gastrointestinal diseases, as well as inhaled formulations for inflammatory lung diseases [2].

Core Insights - A review by RBC Capital Markets identifies about a dozen biotechnology companies as potential acquisition targets, highlighting the interest from buyers in the biotech sector [1] Group 1: M&A Speculation and Investment Opportunities - The review emphasizes how media speculation on biotech mergers and acquisitions can create tactical trading opportunities for investors [2] - RBC analyst Leonid Timashev analyzed reports from major publications and found around 85 reports on M&A since 2021, indicating a significant volume of speculation [2] Group 2: Performance Metrics of M&A Reports - There are notable discrepancies in the "hit rate" of M&A reports from different publications, with Betaville at 20-30% and others like Bloomberg and The Financial Times at 60-70% [3] - Shareholder returns were significantly higher for those who owned shares before M&A announcements, with median returns reaching 27% over 30 days for Bloomberg and The Financial Times, and 70% over 90 days for the latter [4] Group 3: Potential Acquisition Targets - The analysis identified 13 companies as poised for deal activity, including Arrowhead Pharmaceuticals and Xenon Pharmaceuticals, which recently presented promising data for an epilepsy medication [5] - A detailed list of potential takeover targets includes companies with varying market caps and stock performance, such as: - Revolution Medicines: Market cap $19.5 billion, 1-year stock change 156% - Ascendis Pharma: Market cap $14.0 billion, 1-year stock change 38% - Arrowhead Pharmaceuticals: Market cap $7.8 billion, 1-year stock change 270% - Kymera Therapeutics: Market cap $6.5 billion, 1-year stock change 135% - Rhythm Pharmaceuticals: Market cap $5.8 billion, 1-year stock change 62% - Xenon Pharmaceuticals: Market cap $5.0 billion, 1-year stock change 54% - Dyne Therapeutics: Market cap $3.0 billion, 1-year stock change 46% - Viridian Therapeutics: Market cap $2.9 billion, 1-year stock change 84% - BioCryst Pharmaceuticals: Market cap $2.3 billion, 1-year stock change 19% - Wave Life Sciences: Market cap $2.2 billion, 1-year stock change 22% - Ocular Therapeutix: Market cap $1.9 billion, 1-year stock change 15% - Pharvaris: Market cap $1.7 billion, 1-year stock change 66% - EyePoint: Market cap $1.1 billion, 1-year stock change 122% [6]

Core Viewpoint - ProMIS Neurosciences, Inc. is advancing its research on therapies for Alzheimer's disease and other neurodegenerative disorders, presenting findings at the Alzheimer's & Parkinson's Diseases Conference 2026 [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4]. - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in diseases like Alzheimer's, ALS, and Parkinson's [4][8]. Research and Development - The company will present two scientific posters at the AD/PD™ 2026 conference, showcasing its proprietary discovery platform and its approach to targeting toxic misfolded proteins [1][2]. - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [5][6]. - PMN310 has received Fast Track designation from the U.S. FDA as of July 2025, indicating its potential in treating Alzheimer's disease [5]. Clinical Trials - ProMIS initiated the PRECISE-AD trial, a Phase 1b clinical study to evaluate the safety and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [6][7]. - The trial will assess the effects of PMN310 on biomarkers associated with Alzheimer's pathology and clinical outcomes, with a focus on safety and the risk of ARIA [7]. Presentation Details - The first presentation will focus on a vaccine designed against TDP-43 proteinopathies, while the second will discuss vaccination strategies targeting toxic alpha-synuclein species [3].

CORPORATE PRESENTATION NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for s ...

Michelle Xia is the cofounder, chairwoman and CEO of China-based biotech firm Akeso, which has multiple approved drugs in China to treat cancer.Akeso has captured attention in the biotech world because one of its drugs outperformed Merck's bestseller Keytruda in a head to head Phase 3 trial in 2024.See where she lands on the 2026 #ForbesBillionaires list: https://t.co/JYn52gRk2z (Photo: Akeso) ...

Overview of Sana - Sana is a company that has been operating for approximately 7 years, focusing on significant transformations anticipated in the coming decades [3]. Company Leadership - Steven Harr serves as the President, CEO, and Director of the company, expressing gratitude for the opportunity to present in Miami [2]. Forward-Looking Statements - The company acknowledges the inclusion of forward-looking statements and encourages stakeholders to review risk factors outlined in their recently filed 10-K [2].

Financial Performance - The company reported an earnings per share (EPS) of -$0.23 for March 17, 2026, exceeding the estimated EPS of -$0.37, indicating better-than-expected financial performance despite the negative EPS [1][6] - Revenue reached $365,000, significantly surpassing the estimated revenue of $110,330, showcasing the company's ability to generate higher sales than anticipated [2][6] Clinical Development - The company is advancing its pivotal Phase 2b clinical trial, ELPIS II, which evaluates laromestrocel for treating Hypoplastic Left Heart Syndrome (HLHS), with results expected in the third quarter of 2026, potentially leading to a Biologics License Application (BLA) if successful [3][6] Funding and Financial Position - Longeveron secured a private placement of up to $30 million, with an initial $15 million funded, supporting ongoing projects and initiatives, while maintaining a low debt-to-equity ratio of 0.145, indicating a strong financial position [4] - Despite positive developments, the company faces challenges with a negative price-to-earnings ratio of -0.83 and a negative earnings yield of -1.21%, suggesting current unprofitability [5]

Core Viewpoint - Resverlogix Corp. is experiencing delays in completing its year-end audit, which will prevent the company from meeting the March 31, 2026 deadline for filing its Annual Filings [1] Group 1: Audit and Filing Delays - The company anticipates it will not meet the March 31, 2026 deadline for filing Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025 [1] - The auditor has indicated that the audit of the annual financial statements is unlikely to be completed by the deadline, with an expected completion date of April 10, 2026 [1] Group 2: Management Cease Trade Order - Resverlogix has applied to the Alberta Securities Commission for a management cease trade order (MCTO) that would restrict the trading of the company's securities by its CEO and CFO until the Annual Filings are submitted [2] - The ASC has not yet made a decision on the MCTO application, which could either be granted or result in an issuer cease trade order if delays continue [2] Group 3: Compliance and Reporting - The company is committed to completing the Annual Filings as soon as possible and will issue a news release once they are filed [3] - Until the Annual Filings are submitted, the company will adhere to guidelines set out in NP 12-203, including bi-weekly default status reports [3] Group 4: Insider Trading Blackout - Members of the company's management and other insiders are subject to an insider trading blackout until the Annual Filings are completed [4] - There have been no material business developments since the interim financial reports were filed on November 13, 2025 [4] Group 5: Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases [5] - The company is a leader in epigenetics and is developing a new class of therapies aimed at regulating disease-causing gene expression, particularly focusing on cardiovascular disease and post COVID-19 conditions [6]